



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA**  
**Pharmaceuticals & Therapeutics Committee**  
**Department of Health Care Policy & Financing**

Zoom Webinar:

[https://magellanhealth.zoom.us/webinar/register/WN\\_fnML\\_NPKRLmulf2N9i\\_Dyg](https://magellanhealth.zoom.us/webinar/register/WN_fnML_NPKRLmulf2N9i_Dyg)

Tuesday, April 4, 2023, 1:00-5:00 P.M. MST

**1. Committee Member Introductions**

**2. Unfinished Business and General Orders**

Approval of minutes from January 10, 2023 P&T meeting

Updates from January 10, 2023 P&T Meeting

Non-Opioid Analgesia Agents - Oral & Topical

Opioids - Short-Acting, Fentanyl Preparations, Long-Acting

Anticonvulsants, Oral

Newer Generation Antidepressants

Atypical Antipsychotics - Oral/Topical

Neurocognitive Disorder Agents

Sedative Hypnotics

Skeletal Muscle Relaxants

Stimulants and Related Agents

Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral

Multiple Sclerosis Therapies - Disease Modifying & Symptom Management

Ophthalmics, Immunomodulators

Updates on Mass review drug classes:

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral

Monoamine Oxidase Inhibitors (MAOIs)

Tricyclic Antidepressants (TCAs)

Anti-Parkinson's Agents

Benzodiazepines (Non-Sedative Hypnotic)

Anxiolytics, Non-Benzodiazepine

Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)

Lithium Agents

Ophthalmics, Allergy

Ophthalmics, Anti-Inflammatories

Ophthalmics, Glaucoma

**3. New Business**

Updates from the Prior Authorization Call Center

Improving health care equity, access, and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



## 4. Drug Classes Up for Review

Review of PAH Therapies

PDEIs, Endothelin Antagonists, Prostanoids & Guanylate Cyclase Stimulators

Review of Anti-Psoriatics - Oral & Topical

Review of Immunomodulators, Topical

Atopic Dermatitis, Antineoplastics & Other Agents

Review of Bile Salts

Review of Anti-Emetics - Oral & Non-Oral

Review of GI Motility, Chronic

Review of Hemorrhoidal, Anorectal, and Related Topical Anesthetic Agents

Review of Anticoagulants - Oral & Parenteral

Review of Anti-Platelets

Review of Colony Stimulating Factors

Mass review drug classes:

- Tetracyclines
- Alpha-Blockers
- Beta-Blockers - Single Agent, Anti-Arrhythmics & Combinations
- Calcium Channel Blockers - DHPs & Non-DHPs
- Angiotensin Converting Enzyme (ACE) Inhibitors & Combinations
- Angiotensin Receptor Blockers (ARBs) & Combinations
- Renin Inhibitors & Combinations
- Lipotropics - Bile Acid Sequestrants, Fibrates & Other Agents
- Statins & Combinations
- Acne Agents, Topical
- Acne Agents, Oral Isotretinoin
- Rosacea Agents
- Topical Steroids - Low, Medium, High & Very High Potency
- H. Pylori Treatments
- Pancreatic Enzymes
- Proton Pump Inhibitors
- Non-Biologic Ulcerative Colitis - Oral & Rectal
- Erythropoiesis Stimulating Agents

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview  
improving health care equity, access and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.  
[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Bacon, Business Analyst, [jbacon@magellanhealth.com](mailto:jbacon@magellanhealth.com) and carbon copy: Mohamed Duklef, Clinical Pharmacist, [mohamed.duklef@state.co.us](mailto:mohamed.duklef@state.co.us). Once approved, public comments will be distributed to P&T Committee Members.
- Due to Virtual venue, requests and public comment summaries are due by **March 28<sup>th</sup>, 2023 by 5pm MST.**

## 5. Adjourn

Upcoming Meeting Date: July 11, 2023.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

